Point72 Asia Singapore Pte. Ltd. Makes New $163,000 Investment in Vera Therapeutics, Inc. (NASDAQ:VERA)

Point72 Asia Singapore Pte. Ltd. bought a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,493 shares of the company’s stock, valued at approximately $163,000.

A number of other large investors also recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its stake in Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after buying an additional 688 shares during the last quarter. Arizona State Retirement System increased its position in shares of Vera Therapeutics by 14.4% during the second quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock valued at $358,000 after acquiring an additional 1,250 shares during the last quarter. Ensign Peak Advisors Inc lifted its holdings in Vera Therapeutics by 13.5% during the second quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock worth $425,000 after acquiring an additional 1,400 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Vera Therapeutics by 30.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock worth $272,000 after acquiring an additional 1,737 shares during the period. Finally, American International Group Inc. boosted its position in Vera Therapeutics by 17.6% in the first quarter. American International Group Inc. now owns 19,764 shares of the company’s stock worth $852,000 after purchasing an additional 2,957 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on VERA. Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $51.75.

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $43.44 on Friday. The firm has a market cap of $2.38 billion, a P/E ratio of -21.19 and a beta of 0.99. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average is $38.40 and its 200-day moving average is $39.11. Vera Therapeutics, Inc. has a 12-month low of $9.24 and a 12-month high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 23,125 shares of the stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25. Following the sale, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at $14,182,110.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Marshall Fordyce sold 23,125 shares of the business’s stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the completion of the transaction, the chief executive officer now directly owns 307,972 shares in the company, valued at approximately $14,182,110.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Beth C. Seidenberg sold 1,177 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total value of $49,445.77. Following the completion of the sale, the director now owns 160,376 shares in the company, valued at approximately $6,737,395.76. The disclosure for this sale can be found here. Insiders sold 54,398 shares of company stock valued at $2,275,656 in the last quarter. 21.70% of the stock is currently owned by corporate insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.